Daily variation in lung function in COPD patients with combined albuterol and ipratropium: Results from a 4-week, randomized, crossover study

Conclusions The free combination of albuterol and ipratropium resulted in greater improvements and lower day-to-day variability in FEV1 compared with either monotherapy or no bronchodilator therapy. The reduced daily variability may be an important therapeutic advantage of using different classes of bronchodilators in COPD. Trial registration NCT01691482.
Source: Pulmonary Pharmacology and Therapeutics - Category: Respiratory Medicine Source Type: research